Sigh of relief for people with diabetes as FDA approves first biosimilar insulin product

US – The U.S. Food and Drug Administration (FDA) has approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Approvals of these insulin products is set to provide diabetic patients with additional safe, high-quality and potentially cost-effective options for treating diabetes. Semglee, the approved insulin product, is both biosimilar to, and interchangeable with, its reference product Lantus (insulin glargine), a long-acting insulin analog. Biological products include medications for treating…

Read More

Bayer’s Kerendia can now be used in USA as therapy for chronic kidney disease in type 2 diabetes patients

US – Bayer’s first-in-class nonsteroidal drug Kerendia is now available in the US for use following an approval as a therapy that can slow chronic kidney disease progression in patients with type 2 diabetes. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. Kerendia also lowered the risk of a composite of time to first occurrence of cardiovascular…

Read More

Diabetes tech market continues to witness an upward trend as more companies are coming up with new innovations

US – Despite the volatility of last year’s economy due to the corona virus pandemic, diabetes technology companies experienced tremendous success. Analysts have been bullish on the market as companies target new patient populations and major product launches have been planned for 2021 with clinicians approving of the same. Recent surveys of healthcare professionals projecting both the use of continuous glucose monitors and insulin pumps to jump in the coming years. While continuous glucose monitoring (CGMs) and insulin pumps are the primary devices in diabetes tech, the space is also…

Read More

Lilly’s tirzepatide tops list ahead of ozempic as treatment candidate for type 2 diabetes

US – In the just concluded phase 3 trials, the American pharmaceutical company, Eli Lilly have provided results that showed its investigational Gastric inhibitory polypeptide (GIP) and Glucagon-like peptide 1 (GLP-1) inhibitor tirzepatide is superior to Novo Nordisk’s ozempic. The SURPASS-2 study compared the efficacy and safety of tirzepatide 5 mg, 10 mg and 15 mg to Ozempic (semaglutide) 1 mg in adults with inadequately controlled type 2 diabetes, as an add-on to metformin, a prescription medication used to treat diabetes. All three doses of Lilly’s drug demonstrated superior HbA1C…

Read More